Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Emerging Technologies & Paradigms for In Vitro Dx Europe 2024

Adam Hall's Biography



Adam Hall, Associate Professor of Biomedical Engineering, Wake Forest School of Medicine

Adam R. Hall received his training in physics and materials sciences at the University of North Carolina at Chapel Hill, where he was a NASA Graduate Student Research Program (GSRP) Fellow and received the Ross & Charlotte Johnson Family Dissertation Fellowship. He then spent three years as a postdoctoral researcher at Technische Universitat Delft in the Netherlands. From 2010-13, he was an Assistant Professor of Nanoscience at the Joint School of Nanoscience and Nanoengineering in Greensboro, NC, where he earned awards for both his research activities and teaching. He joined the faculty of the Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences in August of 2013 as an Assistant Professor in the Wake Forest School of Medicine. He was promoted to Associate Professor with tenure in 2021 and was appointed Assistant Director of Translational Research for the Atrium Wake Forest Comprehensive Cancer Center in 2023. Dr. Hall has published more than 50 journal articles, is an inventor on 5 patents, and his research has been supported by diverse agencies including the National Institutes of Health (NCI, NIGMS, NIBIB, and NHGRI), DoD, BARDA, 3M, and the North Carolina Biotechnology Center. His research focuses on translational applications of micro- and nanotechnologies.

Adam Hall Image

Translational Detection of Diverse Biomarkers Using Solid-State Nanopore Detectors

Monday, 18 March 2024 at 11:00

Add to Calendar ▼2024-03-18 11:00:002024-03-18 12:00:00Europe/LondonTranslational Detection of Diverse Biomarkers Using Solid-State Nanopore DetectorsEmerging Technologies and Paradigms for In Vitro Dx Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Nanopore technology is uniquely capable to probing large populations of molecules electrically and on an individual basis. While biological (i.e. protein-based) nanopores have found utility in commercial analytical technologies like DNA and RNA sequencing devices (e.g. Oxford Nanopore), their artificial counterparts have so far been less successful in finding a translational foothold. This is at least partially because few straightforward measurements have been demonstrated for the platform to analyze translationally or clinically important markers that cannot easily be probed with existing technologies. In this presentation, I will discuss our progress in developing solid-state nanopore assays capable of assessing several molecular targets that are difficult to probe by other means. These will include DNA epigenetic modification/lesions, microRNAs, and the glycan hyaluronan.


Add to Calendar ▼2024-03-18 00:00:002024-03-19 00:00:00Europe/LondonEmerging Technologies and Paradigms for In Vitro Dx Europe 2024Emerging Technologies and Paradigms for In Vitro Dx Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com